Related Experiment Videos
[Cognitive impairment, clinic forms and progression in multiple sclerosis].
1Hospital Universitario La Fe, Avda. Campanar, 21. E-460009 Valencia, Spain. llandetep@meditex.es
Revista De Neurologia
|June 14, 2003
Summary
Cognitive impairment in multiple sclerosis (MS) significantly impacts patients but is challenging to measure. Future trials will establish best practices for assessing MS-related cognitive changes.
Area of Science:
- Neurology
- Neuropsychology
- Clinical Trials
Background:
- Multiple sclerosis-related cognitive impairment is prevalent and functionally significant.
- Cognitive deficits correlate with cerebral pathology, independent of physical disability.
Framework:
- Neuropsychological assessments are crucial for evaluating multiple sclerosis (MS) clinical trial outcomes.
- Current measures face challenges due to performance heterogeneity and limited understanding of longitudinal changes.
Implementation:
- Standardizing neuropsychological tests is vital for reliable cross-sectional and longitudinal assessments in MS.
- Further research is needed to understand the evolution of cognitive impairment and psychometric properties of measures.
Implications:
- Data from recent trials will inform the selection of optimal neuropsychological measures for future MS studies.
- Establishing criteria for clinically significant cognitive change is essential for patient care and trial interpretation.